001     284644
005     20240229155054.0
024 7 _ |a 10.15252/embr.202357912
|2 doi
024 7 _ |a pmid:37818799
|2 pmid
024 7 _ |a 1469-221X
|2 ISSN
024 7 _ |a 1469-3178
|2 ISSN
024 7 _ |a altmetric:155320629
|2 altmetric
037 _ _ |a DKFZ-2023-02047
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Magalhães, Vladimir G
|0 0000-0002-4593-3467
|b 0
|e First author
245 _ _ |a Immune-epithelial cell cross-talk enhances antiviral responsiveness to SARS-CoV-2 in children.
260 _ _ |a Hoboken, NJ [u.a.]
|c 2023
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1702389983_9556
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2023 Dec 6;24(12):e57912 / #EA:F170#LA:F170#
520 _ _ |a The risk of developing severe COVID-19 rises dramatically with age. Schoolchildren are significantly less likely than older people to die from SARS-CoV-2 infection, but the molecular mechanisms underlying this age-dependence are unknown. In primary infections, innate immunity is critical due to the lack of immune memory. Children, in particular, have a significantly stronger interferon response due to a primed state of their airway epithelium. In single-cell transcriptomes of nasal turbinates, we find increased frequencies of immune cells and stronger cytokine-mediated interactions with epithelial cells, resulting in increased epithelial expression of viral sensors (RIG-I, MDA5) via IRF1. In vitro, adolescent peripheral blood mononuclear cells produce more cytokines, priming A549 cells for stronger interferon responses to SARS-CoV-2. Taken together, our findings suggest that increased numbers of immune cells in the airways of children and enhanced cytokine-based interactions with epithelial cells tune the setpoint of the epithelial antiviral system. Our findings shed light on the molecular basis of children's remarkable resistance to COVID-19 and may suggest a novel concept for immunoprophylactic treatments.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a RIG-I like receptors
|2 Other
650 _ 7 |a SARS-CoV-2
|2 Other
650 _ 7 |a age-dependence of disease
|2 Other
650 _ 7 |a children
|2 Other
650 _ 7 |a interferon response
|2 Other
700 1 _ |a Lukassen, Sören
|b 1
700 1 _ |a Drechsler, Maike
|0 P:(DE-He78)a931c8f45b0ade8be06a288982035fe3
|b 2
|u dkfz
700 1 _ |a Loske, Jennifer
|b 3
700 1 _ |a Burkart, Sandy
|0 P:(DE-He78)72f5852dfc0494f28b35adabf44cacef
|b 4
700 1 _ |a Wüst, Sandra
|0 P:(DE-He78)06a6077b0cfcb0f4890fb5f2543c43be
|b 5
|u dkfz
700 1 _ |a Jacobsen, Eva-Maria
|0 0000-0003-4750-0136
|b 6
700 1 _ |a Röhmel, Jobst
|b 7
700 1 _ |a Mall, Marcus A
|0 0000-0002-4057-2199
|b 8
700 1 _ |a Debatin, Klaus-Michael
|b 9
700 1 _ |a Eils, Roland
|b 10
700 1 _ |a Autenrieth, Stella
|0 P:(DE-He78)d3dbba28fe1239effd15962787cbc363
|b 11
|u dkfz
700 1 _ |a Janda, Aleš
|0 0000-0001-5604-8378
|b 12
700 1 _ |a Lehmann, Irina
|b 13
700 1 _ |a Binder, Marco
|0 P:(DE-He78)2fb2bd9048a3777dddc4cb89b115c187
|b 14
|e Last author
|u dkfz
773 _ _ |a 10.15252/embr.202357912
|g p. e57912
|0 PERI:(DE-600)2025376-X
|n 12
|p e57912
|t EMBO reports
|v 24
|y 2023
|x 1469-221X
909 C O |p VDB
|o oai:inrepo02.dkfz.de:284644
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 0000-0002-4593-3467
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)a931c8f45b0ade8be06a288982035fe3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)72f5852dfc0494f28b35adabf44cacef
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)06a6077b0cfcb0f4890fb5f2543c43be
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)d3dbba28fe1239effd15962787cbc363
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)2fb2bd9048a3777dddc4cb89b115c187
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-08-32
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-32
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-32
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO REP : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EMBO REP : 2022
|d 2023-10-24
920 2 _ |0 I:(DE-He78)F170-20160331
|k F170
|l F170 Virus-assoziierte Karzinogenese
|x 0
920 1 _ |0 I:(DE-He78)F170-20160331
|k F170
|l F170 Virus-assoziierte Karzinogenese
|x 0
920 1 _ |0 I:(DE-He78)F171-20160331
|k F171
|l Dentritische Zellen bei Infektionen und Krebs
|x 1
920 0 _ |0 I:(DE-He78)F170-20160331
|k F170
|l F170 Virus-assoziierte Karzinogenese
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F170-20160331
980 _ _ |a I:(DE-He78)F171-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21